锦波生物(832982) - 2024 Q1 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for Q1 2024 is projected to be between 85 million to 105 million CNY, representing a year-on-year increase of 97.65% to 144.16% compared to 43 million CNY in the same period last year[3]. - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the Q1 2024 report[2][9]. Research and Development - The company has increased its R&D investment and is actively developing new products and product upgrades, contributing to sustainable revenue growth[8].